Navigation Links
Protein overexpression at heart of heart failure

Chronic heart failure resulting from dilated cardiomyopathy is rapidly emerging as a disease of epidemic proportions.1 Molecular mechanisms are being studied and advances have been made in a minority of cases, e.g.: the familial forms. Intracellular [Ca2+]i homeostasis is essential for normal cardiac function and integrity, and dysregulation of [Ca2+]i is a hallmark of advanced heart failure.2 The primary trigger for cardiac [Ca2+]i transients is calcium entry through the pore subunit of the voltage-dependent L-type channels (L-VDCC), but their role in heart failure is still controversial. Electrophysiological studies on individual L-VDCCs from failing human heart have revealed an increased single-channel activity but the mechanism for this biophysical phenotype has remained unknown.3,4

In a paper in this week’s PLoS ONE, Roger Hullin of the Swiss Heart Center Bern, Jan Matthes of University of Cologne, Germany, and collaborators in both Germany and the USA demonstrate an up-regulation of expression of an accessory subunit of the L-VDCC complex (beta 2-subunit) that is responsible for the altered channel behavior in human heart failure. Similar changes of both beta-subunit expression and single-channel behavior were also observed in a mouse model of heart failure with cardiac overexpression of the human L-type Ca2+-channel pore. The causal role of the increased beta 2-subunit expression for the “heart failure type?of single L-VDCC characteristics was proven when the authors developed a novel, cardiac-specific, drug-inducible beta 2a subunit overexpression transgenic mouse which was crossbred with the channel pore overexpressing mouse when still nonfailing (“Adaptive phase?. In the nonfailing double transgenics, the induction of beta 2a protein expression increased the activity of single ventricular L-VDCC, rendering these channels phenotypically identical to human and mouse heart failure.

The authors conclude that electrical remodeling of the L-VDCC , based on gene expression changes, is an early step in a cascade ultimately induced in heart failure. This provides a rational framework for novel therapeutic intervention in heart failure.
'"/>

Source:Public Library of Science


Related biology news :

1. Quantum Dots Research Leads to New Knowledge about Protein Binding in Plants
2. Protein discovery could unlock the secret to better TB treatment
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. An HIV Protein Plays a Surprising Role in Gene Activation
5. Protein Packages Found To Activate Genes; May Be What Regulates Development And Disease
6. New SARS Protein Linked To Important Cell Doorway
7. The Shapes Of Life: NIGMS Project Yields More Than 1,000 Protein Structures
8. PANTHER Protein Classification System Database 5.0
9. Duke Chemists Isolating Individual Molecules Of Toxic Protein In Alzheimers, Parkinsons Disease
10. Newly Discovered Compound Blocks Known Cancer-Causing Protein
11. UF Researchers Map Bacterial Proteins That Cause Tooth Loss

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 ... Family of Companies (Avamere Health Services, Infinity Rehab, Signature ... research study that will apply the power of IBM ... living and health centers. By analyzing data streaming from ... insights into physical and environmental conditions, and obtain deeper ...
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... DIEGO , March 29, 2017  Halozyme ... novel oncology and drug-delivery therapies, today announced that ... Food and Drug Administration voted 11 to 0 ... the skin) injection was favorable for patients in ... B-cell lymphoma and chronic lymphocytic leukemia. The FDA ...
(Date:3/29/2017)... ... 2017 , ... Cancer diagnostics and pathology workflow solution provider ... Association of Community Cancer Centers (ACCC) 43rd Annual Meeting, CANCERSCAPE at ... stakeholders from leading national organizations to share insights on how value-based care, drug ...
(Date:3/29/2017)... SAN DIEGO and NEWARK, Del. ... Inc. , a privately-held regenerative medicine company, and ... global materials science company, today announced a collaborative research ... develop novel implantable cell therapy delivery device technologies that ... more than a decade, ViaCyte has been developing innovative ...
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 ... "Agricultural Biotechnology: Emerging Technologies and Global Markets" report to ... ... (i.e., next generation DNA sequencing, biochips, RNA interference, synthetic biology ... biotech seeds; and biologicals. These technologies and products ...
Breaking Biology Technology: